AstraZeneca: good news for Ultomiris and Enhertu
(CercleFinance.com) - AstraZeneca has announced positive results from a Phase III trial of Ultomiris (ravulizumab-cwvz) showing a statistically and clinically significant reduction in the risk of relapse in adult patients with neuromyelitis optica spectrum disorder (NMOSD) positive (Ac+) compared to the placebo arm.
No relapses were observed in 58 patients over a median treatment duration of 73 weeks.
NMOSD is a rare and devastating autoimmune disease that affects the central nervous system (CNS), including the spine and optic nerves.
The group also announced that the US FDA has approved Enhertu (trastuzumab deruxtecan) for use in a prior metastatic setting as a treatment for metastatic breast cancer.
Enhertu was already established as a last-line treatment for patients with HER2-positive metastatic breast cancer. Administering Enhertu earlier in patients' treatment could potentially delay disease progression, a related source said.
The AstraZeneca share is currently flat in London.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
No relapses were observed in 58 patients over a median treatment duration of 73 weeks.
NMOSD is a rare and devastating autoimmune disease that affects the central nervous system (CNS), including the spine and optic nerves.
The group also announced that the US FDA has approved Enhertu (trastuzumab deruxtecan) for use in a prior metastatic setting as a treatment for metastatic breast cancer.
Enhertu was already established as a last-line treatment for patients with HER2-positive metastatic breast cancer. Administering Enhertu earlier in patients' treatment could potentially delay disease progression, a related source said.
The AstraZeneca share is currently flat in London.
Copyright (c) 2022 CercleFinance.com. All rights reserved.